Literature DB >> 22146873

Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics.

Marjolein P M Hensgens1, Abraham Goorhuis, Olaf M Dekkers, Ed J Kuijper.   

Abstract

BACKGROUND: Clostridium difficile infections (CDIs) are common in developed countries and affect >250,000 hospitalized patients annually in the USA. The most important risk factor for the disease is antibiotic therapy.
METHODS: To determine the period at risk for CDI after cessation of antibiotics, we performed a multicentre case-control study in the Netherlands between March 2006 and May 2009. Three hundred and thirty-seven hospitalized patients with diarrhoea and a positive toxin test were compared with 337 patients without diarrhoea. Additionally, a control group of patients with diarrhoea due to a cause other than CDI (n=227) was included.
RESULTS: In the month prior to the date of inclusion, CDI patients more frequently used an antibiotic compared with non-diarrhoeal patients (77% versus 49%). During antibiotic therapy and in the first month after cessation of the therapy, patients had a 7-10-fold increased risk for CDI (OR 6.7-10.4). This risk declined in the period between 1 and 3 months after the antibiotic was stopped (OR 2.7). Similar results were observed when the second control group was used. All antibiotic classes, except first-generation cephalosporins and macrolides, were associated with CDI. Second- and third-generation cephalosporins (OR 3.3 and 5.3, respectively) and carbapenems (OR 4.7) were the strongest risk factors for CDI. Patients with CDI used more antibiotic classes and more defined daily doses, compared with non-diarrhoeal patients.
CONCLUSIONS: Antibiotic use increases the risk for CDI during therapy and in the period of 3 months after cessation of antibiotic therapy. The highest risk for CDI was found during and in the first month after antibiotic use. Our study will aid clinicians to identify high-risk patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22146873     DOI: 10.1093/jac/dkr508

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  102 in total

Review 1.  [Coronary heart disease and its differential treatment].

Authors:  M Diewitz
Journal:  Med Welt       Date:  1975-10-24

2.  A Systematic Review and Meta-analysis of Antibiotic Treatment Duration for Bacteremia Due to Enterobacteriaceae.

Authors:  Giannoula S Tansarli; Nikolaos Andreatos; Elina E Pliakos; Eleftherios Mylonakis
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

3.  Core elements of hospital antibiotic stewardship programs from the Centers for Disease Control and Prevention.

Authors:  Loria A Pollack; Arjun Srinivasan
Journal:  Clin Infect Dis       Date:  2014-10-15       Impact factor: 9.079

4.  Epidemiology and outcomes of community-acquired Clostridium difficile infections in Medicare beneficiaries.

Authors:  Courtney E Collins; M Didem Ayturk; Julie M Flahive; Timothy A Emhoff; Frederick A Anderson; Heena P Santry
Journal:  J Am Coll Surg       Date:  2014-02-28       Impact factor: 6.113

5.  Cumulative Effect of an Antimicrobial Stewardship and Rapid Diagnostic Testing Bundle on Early Streamlining of Antimicrobial Therapy in Gram-Negative Bloodstream Infections.

Authors:  P B Bookstaver; E B Nimmich; T J Smith; J A Justo; J Kohn; K L Hammer; C Troficanto; H A Albrecht; M N Al-Hasan
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

Review 6.  The Intersection Between Colonization Resistance, Antimicrobial Stewardship, and Clostridium difficile.

Authors:  Rossana Rosa; Curtis J Donskey; L Silvia Munoz-Price
Journal:  Curr Infect Dis Rep       Date:  2018-06-07       Impact factor: 3.725

Review 7.  Fidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance.

Authors:  Kathleen Mullane
Journal:  Ther Adv Chronic Dis       Date:  2014-03       Impact factor: 5.091

8.  Proton Pump Inhibitors Do Not Increase Risk for Clostridium difficile Infection in the Intensive Care Unit.

Authors:  David M Faleck; Hojjat Salmasian; E Yoko Furuya; Elaine L Larson; Julian A Abrams; Daniel E Freedberg
Journal:  Am J Gastroenterol       Date:  2016-08-30       Impact factor: 10.864

Review 9.  Clostridium Difficile Infection from a Surgical Perspective.

Authors:  Andreas M Kaiser; Rachel Hogen; Liliana Bordeianou; Karim Alavi; Paul E Wise; Ranjan Sudan
Journal:  J Gastrointest Surg       Date:  2015-04-28       Impact factor: 3.452

10.  Genome Location Dictates the Transcriptional Response to PolC Inhibition in Clostridium difficile.

Authors:  Erika van Eijk; Ilse M Boekhoud; Ed J Kuijper; Ingrid M J G Bos-Sanders; George Wright; Wiep Klaas Smits
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.